GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lexaria Bioscience Corp (NAS:LEXXW) » Definitions » YoY EPS Growth

LEXXW (Lexaria Bioscience) YoY EPS Growth : 0.00% (As of May. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Lexaria Bioscience YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Lexaria Bioscience's YoY EPS Growth for the quarter that ended in May. 2024 was 0.00%.

Lexaria Bioscience's Earnings per Share (Diluted) for the three months ended in May. 2024 was $0.00.

Lexaria Bioscience YoY EPS Growth Historical Data

The historical data trend for Lexaria Bioscience's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lexaria Bioscience YoY EPS Growth Chart

Lexaria Bioscience Annual Data
Trend Oct13 Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Lexaria Bioscience Quarterly Data
Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Lexaria Bioscience YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Lexaria Bioscience's YoY EPS Growth for the fiscal year that ended in Aug. 2023 is calculated as:

YoY EPS Growth (A: Aug. 2023 )
=(Earnings per Share (Diluted) (A: Aug. 2023 )-Earnings per Share (Diluted) (A: Aug. 2022 ))/ | Earnings per Share (Diluted) (A: Aug. 2022 ) |
=(0-0)/ | 0 |
=N/A %

Lexaria Bioscience's YoY EPS Growth for the quarter that ended in May. 2024 is calculated as:

YoY EPS Growth (Q: May. 2024 )
=(Earnings per Share (Diluted) (Q: May. 2024 )-Earnings per Share (Diluted) (Q: May. 2023 )) / | Earnings per Share (Diluted) (Q: May. 2023 )) |
=(0-0)/ | 0 |
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lexaria Bioscience YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Lexaria Bioscience's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Lexaria Bioscience Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lexaria Bioscience Corp (NAS:LEXXW) » Definitions » YoY EPS Growth
Comparable Companies
PHGE MBIO MYMD APM BCLI GNPX SEEL NNVC LABP VBIV OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XKRX:068270 BNTX ALNY
Traded in Other Exchanges
LEXX:USA
Address
740 McCurdy Road, Suite 100, Kelowna, BC, CAN, V1X 2P7
Website
https://www.lexariabioscience.com
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. The Company has four reportable segments: Intellectual Property Licensing, B2B Production, Research and Development and Corporate. It earns maximum revenue from Intellectual Property Licensing.